Department of Radiation Oncology, University of California, Los Angeles, California.
National Cancer Institute, Division of Cancer Control and Population Sciences, Outcomes Research Branch, Rockville, Maryland.
Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):44-52. doi: 10.1016/j.ijrobp.2018.04.048. Epub 2018 Jun 5.
To improve assessment of symptomatic toxicity in cancer clinical trials and complement clinician-based toxicity reporting, the US National Cancer Institute developed a measurement system called the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). The objective of this study was to examine the content validity of PRO-CTCAE in patients undergoing radiation therapy and to establish anatomic site-specific item sets for implementation in cancer research.
Patients receiving radiation to the brain, head and neck, breast, thorax, abdomen, or pelvis were recruited during the final week of radiation. Participants described side effects qualitatively and completed anatomic site-specific checklists indicating the presence or absence of symptomatic toxicities drawn from the PRO-CTCAE library. Items endorsed by ≥20% of participants were selected for inclusion. Symptomatic toxicities described qualitatively were content analyzed and summarized. Symptomatic toxicities not reflected in the PRO-CTCAE item library were tabulated.
We conducted 389 interviews of patients receiving radiation to the brain (n = 46), head and neck (n = 69), breast (n = 134), thorax (n = 30), abdomen (n = 27), female pelvis (n = 36), or male pelvis (n = 47). Median age was 62 years; 62% were female. The 53 solicited PRO-CTCAE symptoms reflected all reported radiation-induced toxicities with the exception of phlegm/mucus production and mouth/throat pain with swallowing in patients receiving head and neck radiation, eye dryness/irritation in patients undergoing brain radiation, and obstructive urinary symptoms in men receiving pelvic radiation. The PRO-CTCAE items "skin burns" and "pain" require greater specificity to adequately reflect toxicities experienced during radiation.
PRO-CTCAE demonstrates strong content validity as a measure of symptomatic toxicities in patients receiving radiation. These results provide empirical support for the definition of site-specific PRO-CTCAE item sets to assess the symptomatic toxicities of radiation therapy. The site-specific PRO-CTCAE item sets developed herein are currently being deployed in our department via an electronic platform to capture treatment-related toxicity.
为了提高癌症临床试验中症状性毒性的评估水平,并补充以临床医生为基础的毒性报告,美国国立癌症研究所开发了一种名为患者报告结局版通用不良事件术语标准(PRO-CTCAE)的测量系统。本研究的目的是检验在接受放射治疗的患者中,PRO-CTCAE 的内容效度,并为癌症研究建立特定解剖部位的项目集。
在放射治疗的最后一周,招募了接受脑部、头颈部、胸部、腹部或骨盆放射治疗的患者。参与者对副作用进行定性描述,并完成特定解剖部位的检查表,表明从 PRO-CTCAE 库中提取的症状性毒性的存在或不存在。选择被≥20%的参与者认可的项目纳入。对定性描述的症状性毒性进行内容分析和总结。未反映在 PRO-CTCAE 项目库中的症状性毒性进行列表记录。
我们对 46 例接受脑部放射治疗的患者(n=46)、69 例接受头颈部放射治疗的患者(n=69)、134 例接受乳房放射治疗的患者(n=134)、30 例接受胸部放射治疗的患者(n=30)、27 例接受腹部放射治疗的患者(n=27)、36 例接受女性骨盆放射治疗的患者(n=36)或 47 例接受男性骨盆放射治疗的患者(n=47)进行了 389 次访谈。中位年龄为 62 岁;62%为女性。53 个征询问的 PRO-CTCAE 症状反映了除接受头颈部放射治疗的患者出现的痰/粘液产生和吞咽时的咽喉疼痛、接受脑部放射治疗的患者出现的眼睛干燥/刺激以及接受骨盆放射治疗的男性出现的尿路梗阻症状外,所有报告的放射诱导毒性。PRO-CTCAE 的项目“皮肤灼伤”和“疼痛”需要更具体的描述,以充分反映放射治疗期间的毒性。
PRO-CTCAE 作为一种测量接受放射治疗的患者症状性毒性的方法,具有很强的内容效度。这些结果为制定特定解剖部位的 PRO-CTCAE 项目集以评估放射治疗的症状性毒性提供了实证支持。本文中开发的特定解剖部位的 PRO-CTCAE 项目集目前正在通过电子平台在我们部门部署,以捕捉与治疗相关的毒性。